(MedPage Today) — Infants given the monoclonal antibody nirsevimab (Beyfortus) to provide passive immunity against respiratory syncytial virus (RSV) had a lower rate of related hospitalizations and severe outcomes than those whose mothers got…
Source link : https://www.medpagetoday.com/pediatrics/rsv/119142
Author :
Publish date : 2025-12-22 20:50:00
Copyright for syndicated content belongs to the linked Source.
